The nootropic and analgesic effects of Semax given via different routes
Manchenko DM, Glazova NYu, Levitskaya NG, Andreeva LA, Kamensky AA, Myasoedov NF
Neuroscience and Behavioral Physiology (2010)
The Manchenko / Glazova / Levitskaya route-dissociation paper: intraperitoneal Semax produces both nootropic and analgesic effects in white rats with different dose-response curves, while intranasal Semax produces a stronger nootropic effect than i.p. but no analgesic effect at all — the operational basis for Semax's clinical nasal-drop route convention.
This is the primary-study companion to the Levitskaya 2008 synthesis review. Manchenko, Glazova, Levitskaya, Andreeva, Kamensky, and Myasoedov — the same Moscow State University Faculty of Biology / Institute of Molecular Genetics group that synthesized Semax — set out to test whether the route of administration changes the spectrum of Semax's CNS effects in white rats.
They compared intraperitoneal (i.p.) vs intranasal (i.n.) administration across a dose range, with two read-outs: a nootropic assay (acquisition of a conditioned passive avoidance reaction to a footshock stimulus) and a Randall-Selitto hindpaw compression analgesia assay. The headline result is a clean dissociation: intraperitoneal Semax produced both nootropic and analgesic effects, with different dose-response curves for the two; intranasal Semax produced a stronger nootropic effect than intraperitoneal at matched doses but no analgesic effect at any dose tested.
The authors interpret this as evidence that the nootropic and analgesic effects of Semax are mediated by different brain structures and mechanisms, and that the intranasal route delivers peptide selectively to nootropic-relevant forebrain targets without engaging the descending analgesic circuitry that systemic i.p. exposure recruits. This is the load-bearing operational result behind the Russian clinical convention of dosing Semax as 0.1% intranasal drops: it specifies the route, decouples cognitive effect from off-target analgesia, and points to qualitatively distinct mechanisms for the two effects rather than a single melanocortin-receptor occupancy curve.
The full body text of the English translation (Neuroscience and Behavioral Physiology 42:264-270) and of the Russian original (Ross Fiziol Zh Im I M Sechenova 96(10):1014-1023) was not directly accessible to the agent-pipeline extraction pass — both are paywalled on Springer and elibrary.ru. The structured extraction below is reconstructed from the published PubMed English abstract, the Springer abstract fragment, the verbatim Levitskaya 2008 review citation of this exact paper, and the route-comparison context in the 2020 Vasileva et al. follow-up using the same paradigm in mice. Specific per-group sample sizes, per-dose latency means, and p-values from the paper's own tables are not asserted unless verifiable from these external sources.
Structural caveats that apply to the underlying study:
-
Single-laboratory program. Inventor-group institutional positioning applies. The route-dissociation finding is not yet independently replicated in a Western laboratory, although the 2020 Vasileva et al. study in BALB/c and C57BL/6 mice (a separate Russian group at the Zakusov Institute) reproduced the same direction of effect — anxiolytic efficacy higher after i.p., nootropic efficacy higher after i.n. — in a different rodent model.
-
Animal model. White outbred rats; group sizes per behavioral assay in the Ashmarin-group convention typically run 8 to 15 per condition. The exact n per condition for this paper is not extractable from the abstract.
-
Behavioral assay specificity. The CPAR (conditioned passive avoidance) read-out conflates learning, memory consolidation, and emotional reactivity to the shock stimulus. The Randall-Selitto paw-pressure test measures nociceptive thresholding without distinguishing peripheral from central analgesic mechanisms. Both are standard rodent paradigms; neither is mechanistically specific.
-
Dose-response shape not fully specified in abstract. The abstract states that the dose-response curves for nootropic and analgesic effects of i.p. Semax were qualitatively different ("different dose-response characteristics"). The Ashmarin program's broader work documents inverted-U dose-response for Semax nootropic effects; whether this specific paper documents an inverted-U or monotonic shape for the analgesic curve is in the paper's figures but not in the accessible abstract.
-
Mechanism inferred not directly demonstrated. The "different brain structures and mechanisms" framing is supported by the route dissociation but not directly demonstrated by lesion or receptor-antagonist work in this paper.
07·Member discussion
No member discussion yet.
Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.